Market Overview

UPDATE: Goldman Sachs Reiterates Sell Rating, $62 PT on Humana

Share:
Related HUM
Managed Care Stocks Might Be The Best Defense Against Market Volatility
Jim Cramer Gives His Opinion On Humana, Alibaba And General Electric
Catasys: Promising 2Q 2015 Results With Potential For Significant Growth (Seeking Alpha)

In a report published Wednesday, Goldman Sachs Group reiterated its Sell rating and $62.00 price target on Humana (NYSE: HUM).

Goldman Sachs noted, “The focus of the investor day was the transition to provider-integrated care (owned and risk-contracted) that offers lower cost / higher quality outcomes versus traditional fee-for-service. With Medicare Advantage (MA) driving the majority of revenue and earnings, we think integrated care is the right model to better position Humana for tighter MA reimbursement as health reform rolls through and also the right model to strengthen Humana's role in easing the national Medicare cost crisis in the years ahead.”

Humana closed on Tuesday at $68.29.

Latest Ratings for HUM

DateFirmActionFromTo
Jul 2015SusquehannaMaintainsNeutral
Jul 2015Argus ResearchDowngradesBuyHold
Jul 2015WedbushDowngradesOutperformNeutral

View More Analyst Ratings for HUM
View the Latest Analyst Ratings

Posted-In: Goldman Sachs GroupAnalyst Color Reiteration Analyst Ratings

 

Related Articles (HUM)

View Comments and Join the Discussion!

Get Benzinga's Newsletters